



Bioprocess at a Glance

Discover the world of bio-processing at Eppendorf

Learn more

eppendorf



FEATURES

SPOTLIGHTS

NEWS CRUNCH

COLUMNS

EYE ON CHINA

INSIDE INDUSTRY

BIOBOARD

EVENTS

LATEST UPDATES

» Vol 22, No 11, 1



PR NEWSWIRE

PRNewswire
a cision company

Cedrus Investments Signed Cooperation Agreement with Sinopharm Nutraceuticals Industrial (Shanghai) on 16th November 2018

SHANGHAI, Nov. 21, 2018 /PRNewswire/ -- [Cedrus Investments \("Cedrus"\)](#), a global boutique investment firm, signed a cooperation agreement with Sinopharm Nutraceuticals Industrial (Shanghai) ("Sinopharm Nutraceuticals") on 16th November 2018 in Shanghai for the exploration and execution of **investment opportunities in the pharmaceutical, healthcare and biotechnology industries** by leveraging each other's strengths and resources.



Under this agreement, Cedrus brings access to proprietary deal flow from around the globe, deep technical expertise in the biopharmaceutical industry, diverse international business experience, and the capability to structuring and executing transactions -- acquisitions and licensing-rights deals.

Due to Cedrus' relationships, expertise and network in the life sciences industry, it has access to companies with cutting-edge technologies worldwide, including those in Europe, Australia and North America. Cedrus through its acquisitions of some China intellectual property rights, will **jointly develop these overseas ingenious technologies with Sinopharm Nutraceuticals**, aiming to bring the **innovative technologies** selected by Cedrus and Sinopharm Nutraceuticals to the Chinese market to **address the medical needs for patients in China**.

Sinopharm Nutraceuticals is an independent member of the Sinopharm Group, which is also one of its minority shareholders. The firm invests in new technologies and new medical care business models. For overseas investments, the firm aims to invest in new healthcare technologies and bring them to China. Under this agreement, Sinopharm Nutraceuticals brings **valuable on the ground experience**, including **strong capabilities in integrating a variety of resources, including sales and distribution to hospitals**.

Both companies are committed to helping build the life sciences industry in China by introducing **innovative therapies and technologies** that meet the significant unmet needs of the Chinese population in a **cost-effective** and **efficient manner**.

Mr. Pu Qiang, Chairman of Sinopharm Nutraceuticals said, "I am delighted to have this collaboration with Cedrus, together we aim to bring overseas novel technologies to China which will be beneficial to the country and its people, as well as introducing Chinese ingenious technologies to rest of the world."

Cedrus' Chairman **Mr. Rani Jarkas** said, "I am excited to establish a long-term relationship with Sinopharm Nutraceuticals. This collaboration demonstrates Cedrus' continued commitment to contributing to the growth of the life sciences industry in China and a leading playing in innovative technology investments. I look forward to working closely with Sinopharm Nutraceuticals going forward and contributing positively to the Chinese healthcare industry."

About Cedrus Investments

[Cedrus Investments](#) is a global boutique investment firm that offers expertise in [private wealth management](#), [asset management](#) and [financial advisory services](#) to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit www.cedrusinvestments.com.

NEWS CRUNCH

- news** Asia is the fastest growing region for nutraceuticals
- news** 2018 Nobel Prize in Physiology or Medicine winners
- news** Vitafoods Asia expands by 40 per cent in 2018

PR NEWSWIRE

[Two Posters on DB102 \(Enzastaurin\) Presented at the American Society of Hematology Annual Meeting](#)

SAN DIEGO, 5 hours ago

[Guangzhou's Fuda Cancer Hospital Popularizes Cryotherapy Technology as a Solution for Cancer Without Surgery](#)

GUANGZHOU, China, Mon, Nov 26 2018 6:23 PM

[Golden Meditech Announces FY2018/2019 Interim Results](#)

HONG KONG, Mon, Nov 26 2018 5:41 PM

[MDT Innovations announces that its LINOTAG, a fabric based RFID passes Magnetic Resonance Safety Testing and Proven Suitable and in Compliance with MRI Systems](#)

PETALING JAYA, Malaysia, Mon, Nov 26 2018 8:00 AM

[More news](#)

EDITORS' CHOICE



COLUMNS

Media Enquiry:
Cedrus Investments Ltd.
Amy Sin
+852-3519-2828
information@cedrusinvestments.com

Logo - <http://photos.prnasia.com/prnh/20150930/8521506461LOGO>

SOURCE Cedrus Investments

[Back](#) | [Next story: Supermicro Extends Industry-Leading Portfolio of NVIDIA GPU Servers with New Systems at GTC China](#)



INNOVATION ASIA 2018

24th Dubai International Pharmaceutical & Technology Conference & Exhibition

26 - 28 February 2019
Dubai International Convention & Exhibition Centre
United Arab Emirates
duphat.ae Part of

BioIT World WEST
CONFERENCE & EXPO
March 10-15, 2019 | San Francisco, CA **REGISTER TODAY!**

Register Today! **Molecular Med TRI-CON** March 10-15, 2019 San Francisco, CA

analytica Vietnam
APRIL 3-5 | 2019 | HO CHI MINH CITY

IMMUNIZATION SUSTAINING

APBN Editorial Calendar 2018



Editorial calendar is subjected to changes.

MAGAZINE TAGS

- [About Us](#)

- [Events](#)

- [Available issues](#)

- [Editorial Board](#)

- [Letters to Editor](#)

- [Instructions to Authors](#)

- [Advertise with Us](#)

CONTACT

World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667

» For Editorial Enquiries:
biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements & Media Partnerships Enquiries:
biotech_ad@wspc.com